CAMBRIDGE, Mass., Jan. 3, 2018 /PRNewswire/ — TCR2 Therapeutics, an immuno-oncology company pioneering a novel class of T cell therapies for solid tumors, announced today that its Chief Executive Officer, Garry E. Menzel, Ph.D., will present a corporate overview at the 36th Annual J.P….
